Firmagon (degarelix) / Astellas, Ferring - LARVOL DELTA

Tumor Lysis Syndrome Induced by Hormonal Therapy in Metastatic Prostate Cancer: A Case Report. (PubMed, Cureus) - "Hormone therapy with degarelix was initiated...TLS management was initiated, which included aggressive intravenous hydration, hypouricemic therapy with rasburicase, and correction of electrolyte disturbances...In all reported treatment-related TLS cases in prostate cancer, mortality was universal despite aggressive supportive management. This case illustrates a rare instance of TLS occurring after initiation of gonadotropin-releasing hormone antagonist therapy in metastatic prostate cancer, highlighting the need for careful risk assessment, close biochemical monitoring, and prompt recognition and management of TLS, especially in patients with high tumor burden."

Journal • Acute Kidney Injury • Anorexia • Genito-urinary Cancer • Hematological Disorders • Hematological Malignancies • Hepatology • Metabolic Disorders • Nephrology • Oncology • Pain • Prostate Adenocarcinoma • Prostate Cancer • Renal Disease • Solid Tumor

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (clinicaltrials.gov) - P2 | N=25 | Active, not recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2027 ➔ Nov 2028 | Trial primary completion date: Jan 2027 ➔ Nov 2028

Enrollment closed • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Prostate Adenocarcinoma Diagnosed after Surveying for Unusual Embolic Events: A Case Report. (PubMed, Case Rep Neurol) - "A 66-year-old man experienced deep vein thrombosis of the left femoral vein and underwent catheter-directed thrombolysis followed by rivaroxaban therapy...Hormone therapy with degarelix was initiated. Atrial fibrillation also developed during the hospital stay, and apixaban was prescribed...This case highlights the importance of thorough investigation in patients with unusual thromboembolic events, both arterial and venous. Timely diagnosis and treatment of underlying malignancy are crucial in preventing recurrence of cancer-related stroke."

Journal • Atrial Fibrillation • Cardiovascular • Genito-urinary Cancer • Hematological Disorders • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • Thrombosis

NRG-GU002: Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (clinicaltrials.gov) - P2/3 | N=612 | Completed | Sponsor: NRG Oncology | Active, not recruiting ➔ Completed | Trial completion date: May 2026 ➔ Oct 2025 | Trial primary completion date: May 2026 ➔ Oct 2025

Trial completion • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer (clinicaltrials.gov) - P2 | N=112 | Not yet recruiting | Sponsor: Fudan University

New P2 trial • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial. (PubMed, Eur Urol Oncol) - "Neoadjuvant SRC or MEK inhibition does not appear to mitigate the EMT response to ADT or influence clinical or pathological outcomes."

Clinical • Journal • P2 data • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • CDH2 • MAP2K1 • MAP2K2 • VIM

Impact of androgen deprivation therapy on the cardiovascular functions in men with prostate cancer. (PubMed, Int Urol Nephrol) - "ADT appears to have a negative impact on Cardiovascular health. However, patients who received Degarelix seem to have less pronounced effects on cardiovascular parameters compared to the group who received Non-Degarelix treatments."

Journal • Cardiovascular • Coronary Artery Disease • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

PRESTO: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (clinicaltrials.gov) - P3 | N=504 | Completed | Sponsor: Alliance Foundation Trials, LLC. | Active, not recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ Jun 2025

Trial completion • Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Clinical Effectiveness of Oral Relugolix in Advanced Prostate Cancer: A Structured Review of Current Primary Research. (PubMed, Cureus) - "In the HERO trial, Relugolix achieved castration-level testosterone (<50 ng/dL) in 96.7% of patients, outperforming Leuprolide (88.3%) in both speed (median = 4 days vs. 29 days) and magnitude of suppression...Additional studies confirmed its effectiveness when combined with radiotherapy in comparison with Degarelix...These advantages, along with oral administration, support its use as a viable alternative in clinical practice. Further long-term studies are warranted to confirm sustained outcomes and optimize treatment regimes."

Journal • Review • Cardiovascular • Genito-urinary Cancer • Oncology • Oral Cancer • Prostate Cancer • Solid Tumor

Characteristics of tertiary lymphoid structures in prostate cancer and the impact of neoadjuvant therapy on their formation and maturation. (PubMed, Front Immunol) - "Flow cytometry evaluated immune infiltration in bicalutamide-treated mice, and anti-PD1 was combined with degarelix/bicalutamide in preclinical mouse model. NHT enhances TLS formation, maturation, and immune cell infiltration, suggesting a synergistic role for androgen deprivation in shaping the tumor immune microenvironment. The improved anti-tumor response with combined anti-PD1 and ADT highlights the potential of immunotherapy-endocrine therapy combinations as a promising treatment strategy for PCa."

IO biomarker • Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD20 • CD21 • CD4 • CD8 • FOXP3

Relugolix in treatment of prostate cancer: a review. (PubMed, Arch Ital Urol Androl) - "Relugolix represents a significant advancement in ADT, offering a potent, oral alternative with a rapid onset of action, a superior cardiovascular safety profile, and improved testosterone recovery. It provides clinicians with a valuable option for treating advanced prostate cancer, particularly in patients with cardiovascular comorbidities."

Journal • Cardiovascular • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Effectiveness and safety of degarelix compared to GnRH agonists for prostate cancer: a systematic review and meta-analysis. (PubMed, Aging Male) - "However, degarelix achieved significantly higher castration rates at day 3 (96.5% vs 0%; RR: 356.05, 95%CI: 87.57-1447.68, p < 0.00001) and more sustained testosterone suppression at 12 months (96.1% vs 74.3%; RR: 1.3, 95%CI: 1.02-1.66, p = 0.03). While degarelix is associated with higher overall AE rates, it provides significant benefits in terms of cardiovascular and musculoskeletal safety, rapid testosterone suppression, and lower urinary AEs."

Journal • Retrospective data • Review • Cardiovascular • Genito-urinary Cancer • Musculoskeletal Diseases • Oncology • Prostate Cancer • Solid Tumor

Relationship between [18F]PSMA-1007 PET parameters and biochemical recurrence-free survival in high-risk prostate cancer patients receiving neoadjuvant hormonal treatment. (PubMed, Eur J Nucl Med Mol Imaging) - "Our results indicate that [18F]PSMA-1007 PET might be used to aid in patient stratification for determining which patients would benefit from additional (neo)adjuvant treatment."

Clinical • Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Impact of radiotherapy schedule on PSA outcomes and safety in patients with very-high risk prostate cancer receiving degarelix or an LHRH agonist: Additional analysis of the EORTC 1414 trial (EMUC 2025) - P3 | "More severe AEs were reported in patients treated with HFRT than CFRT, independently of ADT type. Trial registration: EudraCT 2015-005098-19"

Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Membranous Nephropathy with Concurrent THSD7A Staining in Kidney and Prostate Cancer Biopsies: A Case Report (KIDNEY WEEK 2025) - "While malignancy screening was underway, worsening edema and proteinuria up to 12 g/day prompted the start of prednisolone and cyclosporine...Degarelix was started and steroids tapered...Malignancy screening is important in THSD7A-associated MN. Kidney THSD7A-IHC, x200 Prostate THSD7A-IHC, x200"

Biopsy • Case report • Clinical • Glomerulonephritis • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Renal Cell Carcinoma • Renal Disease • Solid Tumor

Adherence to Androgen Deprivation Therapy: Cancer Pharmacists Role in Optimising Care Standards in Regional Hospitals (COSA 2025) - "Across 86 episodes of care, leuprorelin was the most frequently administered (n=45), followed by degarelix (n=25) and goserelin (n=16). This project may also serve as a model for other therapies and disease states, ensuring patients receive regular follow-up regardless of where treatment is supplied. The implementation of an oncology management system in regional hospitals may further enhance future practice in this area."

Adherence • Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Radiotherapy plus Long-term Adjuvant Androgen Deprivation with a Luteinizing Hormone-releasing Hormone Antagonist Versus Agonist in Patients with Very High-risk Localized or Locally Advanced Prostate Cancer: The EORTC GUCG-1414 Phase 3 Randomized Trial. (PubMed, Eur Urol Oncol) - "Degarelix did not improve the PSA nadir response within 6 mo after EBRT in comparison to LHRH agonists, but was associated with lower incidence of CV events among patients with pre-existing CV disease."

Journal • P3 data • Cardiovascular • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: OHSU Knight Cancer Institute | N=32 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • IO biomarker • Trial withdrawal • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • PD-L1

Therapeutic vulnerability of prostate cancer to VPAC antagonism (PCF 2025) - "Also, enzalutamide increased phagocytosis of PC cells in VIP-knockout BMDM relative to untreated control, but not in wildtype, suggesting that VPAC1 serves as an androgen-regulated macrophage-suppressive checkpoint...In the androgen-sensitive Myc-CAP syngeneic model, a potent VIP receptor antagonist, ANT308, increased degarelix-mediated tumor control... VPAC1 is an androgen-regulated macrophage checkpoint. VPAC inhibition with ANT308 leads to anti-tumor phagocytosis and enhances ADT-mediated control of prostate tumors in both adenocarcinoma and mixed adeno-neuroendocrine diseases. Further mechanistic investigation is needed to elucidate the intrinsic versus extrinsic role of VIP/VPAC at those stages, informing the design of clinical trials for ANT308 in PC patients."

Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • AR • IL12A • MYC • SYP

Uncovering Compensatory Innate Immune Checkpoints to Target Aggressive Variant Prostate Cancer (PCF 2025) - "They were then treated with a combination of degarelix and apalutamide (as ARPI). Funding Acknowledgements This work was supported by the Prostate Cancer Foundation 2022 Young Investigator Award (22YOUN10), and the UCSF Prostate Cancer Program 2022 Pilot Research Award. Conflicts of Interest Disclosure Statement The authors have no conflicts of interest to disclose."

IO biomarker • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • APOE • CD47 • PTEN • RB1 • SIRPA • TP53 • TREM2

Comparing the risk of cardiovascular disease between degarelix and gonadotropin-releasing hormone agonists:a systematic review and meta-analysis. (PubMed, Front Oncol) - "However, degarelix reduced the risk of heart failure (HR=0.56, 95% CI: 0.36-0.88; P=0.01). Further clarification on the effects of different androgen deprivation therapy modalities on cardiovascular disease is needed from future and larger prospective randomized controlled trials."

Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Genito-urinary Cancer • Heart Failure • Myocardial Infarction • Oncology • Prostate Cancer • Solid Tumor

RTOG 0815: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - P3 | N=1538 | Completed | Sponsor: Radiation Therapy Oncology Group | Active, not recruiting ➔ Completed

Trial completion • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Local perinerural invasion in sacral plexus in recurrent metastatic adenocarcinoma prostate as seen on 68Ga PSMA PET-CT; a rare finding.Local perinerural invasion in sacral plexus in recurrent metastatic adenocarcinoma prostate as seen on 68Ga PSMA PET-CT; a rare finding. (EANM 2025) - "He received Doectaxel, Degarelix and Denosumab and was reported to be in complete remission biochemically and radiologically for 2 years...He was then started on systemic chemotherapy with Cabazitaxel...Conclusion This case highlights the diagnostic value of PSMA PET/CT in detecting uncommon neuro-oncologic complications of prostate cancer and its role in guiding management. Its high sensitivity in identifying metastatic disease, combined with MRI correlation, aids in distinguishing tumor infiltration from treatment-related changes and guides appropriate management including radioligand therapy in the form of 177Lu/225Ac PSMA therapy."

Metastases • Back Pain • Fibrosis • Genito-urinary Cancer • Immunology • Infectious Disease • Musculoskeletal Pain • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Testosterone Recovery after Cessation of Luteinizing Hormone-Releasing Hormone Antagonists in Treatment of Prostate Cancer (ASTRO 2025) - "Few existing studies report faster testosterone recovery (TR) with relugolix (3 months) than degarelix (9 months) and leuprolide (4 months). Over half of patients receiving LHRH antagonists achieved TR to a laboratory-defined normal range with a median TTR of 4.25 months. Though the median duration of relugolix was longer than degarelix, patients receiving relugolix had a shorter median TTR. No association was found between age and TTR."

Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Monitoring serum estradiol in premenopausal women with hormone receptor-positive breast cancer on adjuvant LHRH agonists. (PubMed, Curr Opin Oncol) - "Although not currently supported by high-level evidence, serum E2 monitoring is widely adopted in clinical practice. Prospective studies and evidence-based recommendations are urgently needed. Emerging strategies to overcome incomplete OFS include LHRH antagonists (e.g., degarelix) and oral SERDs."

Journal • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor